OBJECTIVE: The conditionally replicative adenovirus Ad5/3-Δ24 has a type-3 knob incorporated into the type-5 fiber that facilitates enhanced ovarian cancer infectivity. Preclinical studies have shown that Ad5/3-Δ24 achieves significant oncolysis and anti-tumor activity in ovarian cancer models. The purpose of this study was to evaluate in a phase I trial the feasibility and safety of intraperitoneal (IP) Ad5/3-Δ24 in recurrent ovarian cancer patients. METHODS: Eligible patients were treated with IP Ad5/3-Δ24 for 3 consecutive days in one of three dose cohorts ranging 1 × 10(10)-1 × 10(12)vp. Toxicity was assessed utilizing CTC grading and efficacy with RECIST. Ascites, serum, and other samples were obtained to evaluate gene transfer, generation of wildtype virus, viral shedding, and antibody response. RESULTS: Nine of 10 patients completed treatment per protocol. A total of 15 vector-related adverse events were experienced in 5 patients. These events included fever or chills, nausea, fatigue, and myalgia. All were grades 1-2 in nature, transient, and medically managed. Of the 8 treated patients evaluable for response, six patients had stable disease and 2 patients had progressive disease. Three patients had decreased CA-125 from pretreatment levels one month after treatment. Ancillary biologic studies indicated Ad5/3-Δ24 replication in patients in the higher dose cohorts. All patients experienced an anti-adenoviral neutralizing antibody effect. CONCLUSIONS: This study suggests the feasibility and safety of a serotype chimeric infectivity-enhanced CRAd, Ad5/3-Δ24, as a potential therapeutic option for recurrent ovarian cancer patients.
OBJECTIVE: The conditionally replicative adenovirus Ad5/3-Δ24 has a type-3 knob incorporated into the type-5 fiber that facilitates enhanced ovarian cancer infectivity. Preclinical studies have shown that Ad5/3-Δ24 achieves significant oncolysis and anti-tumor activity in ovarian cancer models. The purpose of this study was to evaluate in a phase I trial the feasibility and safety of intraperitoneal (IP) Ad5/3-Δ24 in recurrent ovarian cancerpatients. METHODS: Eligible patients were treated with IP Ad5/3-Δ24 for 3 consecutive days in one of three dose cohorts ranging 1 × 10(10)-1 × 10(12)vp. Toxicity was assessed utilizing CTC grading and efficacy with RECIST. Ascites, serum, and other samples were obtained to evaluate gene transfer, generation of wildtype virus, viral shedding, and antibody response. RESULTS: Nine of 10 patients completed treatment per protocol. A total of 15 vector-related adverse events were experienced in 5 patients. These events included fever or chills, nausea, fatigue, and myalgia. All were grades 1-2 in nature, transient, and medically managed. Of the 8 treated patients evaluable for response, six patients had stable disease and 2 patients had progressive disease. Three patients had decreased CA-125 from pretreatment levels one month after treatment. Ancillary biologic studies indicated Ad5/3-Δ24 replication in patients in the higher dose cohorts. All patients experienced an anti-adenoviral neutralizing antibody effect. CONCLUSIONS: This study suggests the feasibility and safety of a serotype chimeric infectivity-enhanced CRAd, Ad5/3-Δ24, as a potential therapeutic option for recurrent ovarian cancerpatients.
Authors: Taco G Uil; Toshiro Seki; Igor Dmitriev; Elena Kashentseva; Joanne T Douglas; Marianne G Rots; Jaap M Middeldorp; David T Curiel Journal: Cancer Gene Ther Date: 2003-02 Impact factor: 5.987
Authors: Gerd J Bauerschmitz; John T Lam; Anna Kanerva; Kaori Suzuki; Dirk M Nettelbeck; Igor Dmitriev; Victor Krasnykh; Galina V Mikheeva; Mack N Barnes; Ronald D Alvarez; Peter Dall; Ramon Alemany; David T Curiel; Akseli Hemminki Journal: Cancer Res Date: 2002-03-01 Impact factor: 12.701
Authors: Kenneth H Kim; Igor Dmitriev; Janis P O'Malley; Minghui Wang; Souheil Saddekni; Zhiying You; Meredith A Preuss; Raymond D Harris; Rosemarie Aurigemma; Gene P Siegal; Kurt R Zinn; David T Curiel; Ronald D Alvarez Journal: Clin Cancer Res Date: 2012-04-17 Impact factor: 12.531
Authors: Anna Kanerva; Minghui Wang; Gerd J Bauerschmitz; John T Lam; Renee A Desmond; Snehal M Bhoola; Mack N Barnes; Ronald D Alvarez; Gene P Siegal; David T Curiel; Akseli Hemminki Journal: Mol Ther Date: 2002-06 Impact factor: 11.454
Authors: Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen Journal: J Clin Oncol Date: 2003-07-14 Impact factor: 44.544
Authors: Anna Kanerva; Kurt R Zinn; Tandra R Chaudhuri; John T Lam; Kaori Suzuki; Taco G Uil; Tanja Hakkarainen; Gerd J Bauerschmitz; Minghui Wang; Bin Liu; Zhihong Cao; Ronald D Alvarez; David T Curiel; Akseli Hemminki Journal: Mol Ther Date: 2003-09 Impact factor: 11.454
Authors: Ray M Bernal; Sherven Sharma; Brian K Gardner; Joanne T Douglas; Jeffrey M Bergelson; Steven M Dubinett; Raj K Batra Journal: Clin Cancer Res Date: 2002-06 Impact factor: 12.531
Authors: Evanthia Galanis; Pamela J Atherton; Matthew J Maurer; Keith L Knutson; Sean C Dowdy; William A Cliby; Paul Haluska; Harry J Long; Ann Oberg; Ileana Aderca; Matthew S Block; Jamie Bakkum-Gamez; Mark J Federspiel; Stephen J Russell; Kimberly R Kalli; Gary Keeney; Kah Whye Peng; Lynn C Hartmann Journal: Cancer Res Date: 2014-11-14 Impact factor: 12.701
Authors: Pascal R A Buijs; Judith H E Verhagen; Casper H J van Eijck; Bernadette G van den Hoogen Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452
Authors: Ashley Browne; Laura A Tookman; Carin K Ingemarsdotter; Russell D Bouwman; Katrina Pirlo; Yaohe Wang; Iain A McNeish; Michelle Lockley Journal: Cancer Res Date: 2015-05-14 Impact factor: 12.701